Literature DB >> 8702865

Inhibitor probes of the quinone binding sites of mammalian complex II and Escherichia coli fumarate reductase.

V Yankovskaya1, S O Sablin, R R Ramsay, T P Singer, B A Ackrell, G Cecchini, H Miyoshi.   

Abstract

The structural and catalytic properties of beef heart succinate dehydrogenase (succinate-ubiquinone oxidoreductase, complex II) and Escherichia coli fumarate reductase are remarkably similar. One exception is that whereas electron exchange between the mammalian enzyme and its quinone pool is inhibited by thenoyltrifluoroacetone and carboxanilides, the enzyme from E. coli is not sensitive to these inhibitors. The lack of good inhibitors has seriously hampered the elucidation of the mechanism of quinone oxidation/reduction in the E. coli enzyme. We have previously reported (Tan, A. K., Ramsay, R. R., Singer, T. P., and Miyoshi, H. (1993) J. Biol. Chem. 268, 19328-19333) that 2-alkyl-4,6-dinitrophenols inhibit mammalian complexes I, II, and III, but with different potencies and kinetic characteristics. Based on these studies we have selected a series of 2-alkyl-4,6-dinitrophenols which proved to be very effective noncompetitive inhibitors of mammalian complex II, particularly when acting in the direction of quinone reduction, the physiological event. These compounds turned out to be even more potent inhibitors of E. coli fumarate reductase, particularly when acting in the direction of quinol oxidation, again, the physiological event. Kinetic analysis revealed that with both enzymes 2 inhibitor binding sites seem to be involved in the oxidation of succinate by quinone, but one seems to be functioning when fumarate is reduced by external quinol. Since the E. coli enzyme can be modified by site-directed mutagenesis, these studies were extended to four mutants of fumarate reductase, impaired by single amino acid substitutions at either of the putative quinone binding sites (QA or QB) of the enzyme. The results were analyzed in terms of the model of these dual sites of quinone binding in fumarate reductase, as well as the nature of the substituent in the 2-position of the dinitrophenol inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702865     DOI: 10.1074/jbc.271.35.21020

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Catalytic mechanisms of complex II enzymes: a structural perspective.

Authors:  T M Iverson
Journal:  Biochim Biophys Acta       Date:  2012-09-18

2.  Hydroxylated naphthoquinones as substrates for Escherichia coli anaerobic reductases.

Authors:  R A Rothery; I Chatterjee; G Kiema; M T McDermott; J H Weiner
Journal:  Biochem J       Date:  1998-05-15       Impact factor: 3.857

3.  Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature.

Authors:  Qiangjun Zhou; Yujia Zhai; Jizhong Lou; Man Liu; Xiaoyun Pang; Fei Sun
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

4.  Alternative quinone substrates and inhibitors of human electron-transfer flavoprotein-ubiquinone oxidoreductase.

Authors:  Martin Simkovic; Frank E Frerman
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

5.  Crystallographic investigation of the ubiquinone binding site of respiratory Complex II and its inhibitors.

Authors:  Li-Shar Huang; Peter Lümmen; Edward A Berry
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2021-06-03       Impact factor: 4.125

6.  Alternative splicing isoform in succinate dehydrogenase complex, subunit C causes downregulation of succinate-coenzyme Q oxidoreductase activity in mitochondria.

Authors:  Nana Satoh; Chikako Yokoyama; Noriaki Itamura; Yoshiharu Miyajima-Nakano; Hisashi Hisatomi
Journal:  Oncol Lett       Date:  2014-11-11       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.